Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim study proves telmisartan effectiveness

Boehringer Ingelheim study proves telmisartan effectiveness

2nd April 2008

A study aimed to discover if Micardis (telmisartan) is as effective as ramipril in reducing the risk of various heart conditions and stroke has been successful, Boehringer Ingelheim (BI) has revealed.

BI said its Ontarget study involving 25,620 patients proved that telmisartan is as protective as “current gold standard” ramipril in decreasing risks of myocardial infarction, stroke, congestive heart failure and cardiovascular death.

Results showed that this type of cardiovascular event occurred in 16.66 per cent of subjects using telmisartan and 16.46 per cent of those receiving ramipril.

BI also stated that the success of the study proves telmisartan to be effective in preventing every fifth serious cardiovascular case.

“With 99.8 per cent of patients followed over these years, this is one of the best managed landmark trials ever,” said BI member of the board of managing directors Dr Andreas Barner, who is responsible for the group’s research, development and medicine.

The Ontarget trial was conducted over a period of six years.

Prior to the announcement of results, BI revealed that marketing authorisation for its oral direct thrombin inhibitor Pradaxa had been approved by the European commission.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.